Coronary Stent Market - Strategic Insights and Forecasts (2026-2031)

The Coronary Stent Market is projected to grow from USD 5.880 billion in 2026 to USD 7.540 billion by 2031, registering a CAGR of 5.10% during the forecast period.

Coronary stents are implantable devices deployed during PCI to maintain an opened coronary artery. Drug-eluting stents release an antiproliferative agent from a metallic or other scaffold to limit tissue regrowth; bare-metal devices and fully bioresorbable platforms occupy much smaller clinical niches. Commercial demand consists of finished coronary stent systems sold for implantation, including the delivery catheter supplied with the stent. Diagnostic catheters, balloons sold separately, intravascular imaging systems, peripheral vascular stents and overall PCI procedure fees are distinct markets.

Selection and purchasing are jointly shaped by interventional cardiologists, cardiac-catheterization teams and hospital procurement departments. Abbott’s XIENCE range, Medtronic’s Onyx systems, Boston Scientific’s SYNERGY family and Terumo’s Ultimaster products illustrate the depth of established clinical platforms. Regional suppliers, including MicroPort, SMT and Translumina, compete through drug and polymer configurations, regulatory access and responsive pricing. Health-system tenders are especially influential in high-volume markets where a technically acceptable stent can be purchased from several qualified manufacturers.

Everolimus-, sirolimus- and zotarolimus-eluting stents have displaced most bare-metal devices because controlling neointimal growth reduces the likelihood of restenosis. Differences within the drug-eluting class now matter more to many buyers than the historic distinction between coated and uncoated metal. Polymer persistence, strut thickness, expansion range, deliverability and the evidence supporting abbreviated antiplatelet therapy influence physician preference, particularly for small arteries, bifurcations and patients vulnerable to bleeding.

Abbott introduced XIENCE Skypoint in India in March 2026 with longer lengths and larger diameters, while Terumo’s Ultimaster Nagomi portfolio covers multiple vessel diameters and lengths for more complex anatomy. Medtronic’s Onyx Frontier emphasizes delivery-system performance, and Biosensors International positions BioFreedom Ultra around a polymer-free drug-coated surface.

China demonstrates how substantially the revenue model can diverge from implanted volume. In May 2026, its national purchasing authority reported demand submissions of roughly 2.73 million coronary stents for a renewed centralized-procurement round, alongside broad participation by domestic and multinational suppliers. That scale supports industrial production and treatment access, but negotiated device prices limit the revenue gained per additional procedure.

Market Trends

• Drug-Eluting Platforms Are Extending Their Range of Treatable Lesions

Long diffuse disease and large left-main arteries present contrasting demands: one requires length without excessive overlap, while the other requires substantial and predictable expansion. Abbott’s XIENCE Skypoint portfolio includes a 48 mm configuration and larger-diameter offerings; Terumo’s Ultimaster Nagomi uses vessel-specific designs and extended lengths.

A broader size matrix can alter device use per case. Treating a long lesion with one implant may replace overlapping devices, whereas a difficult bifurcation may require additional equipment and imaging. Product innovation therefore does not translate mechanically into more stents per procedure.

• Bleeding-Risk Evidence Is Reshaping Clinical Differentiation

High-bleeding-risk PCI patients need a balance between prevention of stent thrombosis and the complications associated with prolonged dual antiplatelet therapy. Terumo received an expanded European MDR indication for Ultimaster Nagomi and Ultimaster Tansei in July 2025 covering patients eligible for shortened therapy. Biosensors International likewise markets the BioFreedom Ultra platform around clinical evidence in patients for whom longer antiplatelet treatment is problematic.

The commercial impact is tied to the device’s actual approved labeling and the quality of supporting trials. An attractive coating mechanism alone cannot establish that the same antiplatelet strategy is safe for every patient.

• Centralized Purchasing Is Separating Volume Growth from Revenue Growth

China’s May 2026 second continuation round for coronary-stent volume-based purchasing included 15 bidding companies and 30 products, with 27 products provisionally selected. Procurement demand exceeded the preceding tender cycle, yet competitive selection still places a ceiling on realizable device revenue.

India applies another approach through regulated ceiling prices rather than the same national tender mechanism. The National Pharmaceutical Pricing Authority revised stent ceilings for April 2026, preserving a formal distinction between bare-metal and drug-eluting systems.

• Regulatory Renewal Is Becoming a Competitive Barrier

The European Medical Device Regulation requires continued technical documentation, clinical evaluation and post-market surveillance. MicroPort reported MDR certification in March 2026 for Firehawk and Firehawk Liberty coronary stents, protecting the ability to market those platforms under the newer European rules.

In the United States, the FDA approved an additional 4.5 mm and 5.0 mm size range for BIOTRONIK’s Orsiro Mission in June 2026. The decision is a defined device modification, not evidence of a wholly new stent market.

Coronary Stent Market Segment Analysis

By Type

• Drug-Eluting Stents

Drug-eluting stents remain the default device for a broad range of coronary interventions, spanning stable coronary disease and acute coronary syndromes. Their clinical position rests on established anti-restenotic performance and extensive experience with limus-family agents. Within this category, physicians choose among permanent-polymer, biodegradable-polymer and polymer-free formulations according to lesion characteristics, delivery performance and approved patient indications.

The segment is projected to represent approximately USD 7.16 billion in 2031. Its continuing scale does not eliminate the need for price differentiation: public tenders can support high implant volumes while compressing revenue per device. Improvements in catheter profile and scaffold mechanics are more likely to defend premium positioning in complex cases than general claims that a stent releases a newer drug.

By Delivery Mode

• Balloon-Expandable Stents

Balloon-mounted coronary stents predominate because the operator can position the device at a lesion and control expansion to the desired diameter using a dedicated delivery balloon. The approach is well matched to contemporary metallic drug-eluting platforms, in which radial strength and controlled placement are essential. The underlying balloon is part of the finished stent delivery system; a separate angioplasty balloon used before or after deployment is not counted a second time.

Balloon-expandable products are expected to generate approximately USD 7.49 billion in 2031. Dedicated self-expanding coronary devices remain exceptionally specialized and should not be confused with the much larger peripheral self-expanding stent market.

By End-User

• Hospitals

Hospitals purchase the majority of coronary stents because catheterization laboratories are commonly embedded in acute-care and tertiary facilities, with immediate access to intensive-care, imaging and surgical services when required. Large hospital networks purchase through contracts and inventories that cover multiple stent lengths and diameters.

Hospital purchases are forecast to reach approximately USD 5.28 billion by 2031. Specialist cardiac centers can attract a larger portion of complex elective PCI as treatment networks mature, but the boundary between a cardiac center and a hospital is defined here by the operating and procurement entity, not by whether a building contains a catheterization laboratory.

Market Drivers

• Expansion of Treatable Coronary Disease and PCI Access

Aging populations and persistent exposure to diabetes, hypertension and dyslipidemia contribute to the clinical burden of coronary artery disease. However, population prevalence affects stent demand only when symptomatic patients are diagnosed and receive an intervention rather than medical therapy or bypass surgery. Growth is strongest where cardiac referral pathways, emergency transport and catheterization-laboratory capacity improve together.

Vendors selling into emerging treatment networks need training, reliable supply and a broad diameter-length inventory as well as competitive prices. A hospital with newly commissioned PCI capacity does not immediately generate the same case mix as an established tertiary center; demand usually develops with physician staffing and referral depth.

• More Complex Lesions Require Better Scaffold Engineering

Diffuse lesions, calcified vessels and left-main disease create demanding conditions for device delivery and deployment. Manufacturers use thinner struts, optimized link architecture, higher expansion capability and improved balloon systems to reach difficult anatomy.

Complexity supports product-mix value when clinicians can justify higher-priced devices through procedural reliability or fewer overlapping implants. It does not ensure a proportional increase in the number of stents sold, particularly where physiology or intravascular imaging leads to a different treatment decision.

• Drug-Eluting Clinical Evidence Supports Device Replacement

Drug-eluting platforms have continued to displace bare-metal systems because restenosis risk and repeat intervention matter to patients and health systems. The installed clinical evidence also supports refinements in coatings and drug release, although any new formulation requires adequate comparative data.

Manufacturers with large post-market registries and long follow-up periods can use evidence as a purchasing differentiator. Regional challengers must establish comparable confidence through trials, regulatory submissions and real-world monitoring rather than competing solely on lower unit prices.

• Broader Local Manufacturing and Regulatory Access

Domestic coronary-stent manufacturers in China and India now provide products across a range of drug and polymer architectures. MicroPort’s European MDR renewals and SMT’s Canadian regulatory approval show that regional suppliers are pursuing markets beyond their home countries.

Qualification of local products may support competition and reduce procurement dependence on imports. The outcome for revenue depends on pricing and procurement channels: a successful tender can greatly increase units while leaving only modest additional sales value.

• Established Reimbursement for Coronary Intervention

PCI is supported by established reimbursement pathways in the United States, Canada and much of Europe, giving hospitals a predictable framework for implant decisions. These systems support access to clinically validated stents, but device payments are often embedded within a broader procedure or episode-of-care reimbursement.

Manufacturers that offer reliable clinical outcomes and broad product availability may sustain contracts even without the lowest list price. Conversely, a premium system must show why the added device cost matters when the hospital does not receive a separate incremental payment for the implant.

Market Restraints

• Tender-Led Price Compression

China’s volume-based procurement program demonstrates the difference between growing patient access and growing manufacturer revenue. National purchasing has sharply reduced the selling price of selected coronary stents while giving winning suppliers large volume commitments.

The resulting pressure is concentrated on established designs with several qualified substitutes. Manufacturers must improve production efficiency and keep delivery performance consistent; premium positioning is harder to defend when procurement requirements specify technical equivalence and cap unit spending.

• Long and Expensive Device Qualification

Implantable coronary devices must meet demanding requirements for mechanical durability, coating integrity, biocompatibility and long-term clinical safety. Material changes or altered stent geometry can require new verification, regulatory review and post-market evidence.

European MDR surveillance and FDA approval pathways favor firms capable of sustaining product-line data over multiple years. Qualification spending can delay commercial rollout even when a novel device performs well in bench testing or a limited early clinical study.

• Competing Revascularization and Drug-Coated Balloon Strategies

Stenting is not appropriate for every coronary lesion. Coronary bypass surgery remains relevant for selected multivessel and complex disease, while optimal medical therapy is preferred in some stable patients. Drug-coated balloons increasingly offer a way to treat certain lesions without leaving a second permanent implant, notably in-stent restenosis. Cordis received US FDA approval in September 2026 for its SELUTION SLR coronary drug-eluting balloon for that indication.

These alternatives do not displace the standard role of drug-eluting stents in most new coronary interventions. They nevertheless constrain forecasts that assume every increase in PCI procedures must lead to an equivalent increase in implanted coronary stents.

• Stent Thrombosis, Restenosis and Patient-Specific Risk

The clinical consequences of an unsuccessful coronary implant can be serious, requiring careful lesion assessment and antiplatelet management. Diabetes, lesion length, vessel diameter and bleeding risk affect the choice of device and the acceptable treatment strategy.

Safety considerations also make hospitals reluctant to replace established platforms on price alone. New manufacturers must demonstrate repeatable outcomes in the patient groups that local clinicians actually treat, which can slow adoption after initial regulatory clearance.

• Manufacturing Precision and Supply Dependence

Drug-eluting coronary stents combine finely fabricated metal scaffolds, controlled drug and polymer loading, precision crimping and reliable delivery systems. Small deviations in surface treatment or coating application can affect product uniformity and regulatory compliance.

These constraints become commercially important in tender markets where suppliers have committed to high volumes at fixed prices. A quality event or a shortage of a less common diameter can disrupt hospital supply even when overall factory capacity appears sufficient.

Regional Outlook

• North America

North America accounts for an estimated 34% of coronary-stent market value in 2026, making it the largest regional revenue pool. The United States dominates this position through established PCI reimbursement, specialist interventional services and use of clinically differentiated drug-eluting systems. Pricing is materially higher than in tightly regulated public tenders in parts of Asia.

Regional revenue is expected to reach approximately USD 2.34 billion by 2031. Growth is comparatively measured because treatment pathways are mature, and device innovation may reduce the number of overlapping stents needed in lengthy lesions. Hospitals are likely to continue purchasing established platforms while using competing product bids and bundled procedure economics to manage cost. Canada contributes a smaller but stable clinical market; Mexico offers expansion through specialist cardiovascular services, tempered by procurement and access differences.

• Asia Pacific

Asia Pacific is expected to be the fastest-growing region, with an estimated 7.68% CAGR during 2026–2031. China supplies a very large share of implanted units, supported by high procedural demand and centralized procurement, although its low tender prices hold down average revenue per stent. Japan provides a more mature, higher-value product mix, while India is expanding access to PCI through public and private hospital networks within its regulated stent-price framework.

The region is forecast to account for about 35% of global market value by 2031, overtaking North America in the modeled revenue mix. Growth is uneven rather than a single regional adoption pattern: hospital capacity, import dependence, payer structures and clinical specialization differ markedly across Southeast Asia, India, China, South Korea and Japan.

Competitive Landscape

Abbott, Boston Scientific and Medtronic compete through widely used drug-eluting platforms, extensive clinical research and relationships with major catheterization centers. Their portfolios differ in drug/polymer construction, balloon delivery and device-size choices, but purchasing decisions rarely rest on one technical specification alone.

Terumo and BIOTRONIK participate through clinically differentiated sirolimus-eluting systems, while Biosensors International emphasizes polymer-free biolimus delivery for selected patient groups. MicroPort, Sahajanand Medical Technologies, Translumina and Sino Medical Sciences offer alternative drug and coating architectures and pursue cross-border product registrations.

Recent Developments

• September 2026: Sahajanand Medical Technologies announced Canadian regulatory approval for the Supraflex Cruz coronary stent, extending the geographic reach of its drug-eluting portfolio.

• September 2026: MicroPort Coronary reported that its FireShield coronary covered-stent system entered China’s NMPA innovative-device special review program; this is a regulatory pathway designation, not marketing approval.

• June 2026: The US FDA approved an Orsiro Mission supplement for BIOTRONIK, adding 4.5 mm and 5.0 mm coronary stent diameters and associated manufacturing changes.

• April 2026: MicroPort announced European MDR certification of its Firehawk and Firehawk Liberty sirolimus-eluting coronary stent systems, preserving regulatory access under updated requirements.

• March 2026: Abbott introduced XIENCE Skypoint in India with expanded stent lengths and diameters intended for long or complex coronary lesions.

Market Outlook

Coronary stent demand through 2031 will be shaped by sustained PCI access and changing revenue per implant rather than by a uniform global shift toward premium devices. Mature health systems will continue to pay for verified deliverability, broad size offerings and clinical differentiation, while large national tenders emphasize procurement scale and supply security.

Asia Pacific is positioned to contribute an increasing share of global value, with China driving implant volume and other markets adding opportunities for differentiated products. The commercial success of international manufacturers will depend on local distribution, regulatory approvals and pricing discipline.

Clinical evidence will remain central to product positioning. More data on complex anatomy and antiplatelet management could support established stent families, but drug-coated balloons, bypass surgery and optimized medical therapy will continue to compete where appropriate.

Coronary Stent Market Scope: